anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:The pyrrolidine compound of formula I . USE:The compound has the activities to contract the intestine of Periplaneta Americana (a kind of cockroach) and to kill various cockroaches and housefly, and can be used effectively as an insecticide in various forms. It has low toxicity and high safety to warm-blooded animal and fish, and is stable to light, heat, etc. It can be applied without restrictions in the place and time. The compound is used at a concentration of generally 0.01-0.2%. PREPARATION:A red alga belonging to Chondria armata is extracted with a solvent, and the extract is subjected to one or more treatments selected from adsorption chromatography, ion exchange chromatography and gel chromatography. The fraction containing the isodomoic acid A of formula II and isodomic acid B of formula III is collected, and the compound of formula I which includes the compound of formula II and III can be separated from the fraction.
* Administer everolimus tablets at the same time each day.
  * Administer everolimus tablets consistently either with or without food [see Clinical Pharmacology (12.3)].

  * If a dose of everolimus tablets is missed, it can be administered up to 6 hours after the time it is normally administered. After more than 6 hours, the dose should be skipped for that day. The next day, everolimus should be administered at its usual time. Double doses should not be administered to make up for the dose that was missed.




Everolimus tablets

  * Everolimus tablets should be swallowed whole with a glass of water. Do not break or crush tablets.
The specification shows a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also shown. Furthermore, methods for vaccination using suitable epitopes are shown. More specifically, the invention relates to a broadly neutralizing antibody (bNAb) comprising the polypeptide 4869-K15 (PGT-133), i.e to a monoclonal anti-HIV antibody comprising a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 420 and a light chain sequence comprising the amino acid sequence SEQ ID NO: 429.
FIELD: virology, vaccine production. SUBSTANCE: quail embryo primary trypsinized cultured cells are infected separately with epidemic parotitis virus strain (L-3) and measles virus strain (L-16) followed by incubation on growth medium in the presence of antibiotic and growth proteins. Cells are washed out with supporting medium (6 times, not less for each component) and further incubation and collection of virus-containing liquid is carried out. Stabilizing agent is added to the latter. Prepared liquid monocomponents are frozen and stored up to results of control. Before packaging monocomponents are mixed in the definite ratios to obtain mixed vaccine with required concentrations of components of epidemic parotitis and measles. EFFECT: increased yield of viruses, improved standard of viral material by its specific activity, decreased post-vaccinial and allergic symptoms. 13 cl, 5 ex
Methods for modulating quorum sensing in certain Gram-negative bacteria having multiple QS systems including Las, Rhl, and Pqs with associated receptors (LasR, RhlR and PqsR) which are modulated by small molecule modulators, particularly non-native modulators. Certain combinations of modulators of Las, Rhl and Pqs exhibit improved inhibition of virulence in comparison to the respective individual modulators. In particular, certain combinations of modulators exhibit improved inhibition in nutritionally depleted environments. More specifically, certain combinations of modulators exhibit improved inhibition in environments depleted in phosphate and/or environments depleted in iron. Nutrient depleted environments can mimic environments associated with bacterial infection in humans and non-human animals. The methods are useful in particular for modulating QS in Pseudomonas and Burkholderia.
Additional adverse reactions have been identified during postapproval use of ONGLYZA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  * Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions. [See Contraindications (4) and Warnings and Precautions (5.3).]
  * Acute pancreatitis. [See Indications and Usage (1.2) and Warnings and Precautions (5.1).]
Adhesions and scar formation following a surgical procedure are controlled by providing a human recombinant phage antibody, and introducing the antibody onto or into an area of the body following the procedure to inhibit adhesions, or scar formation. According to one embodiment, the antibody is used to prevent the formation of scar tissue following spinal surgery. This may be carried out by placing the antibody over the dura lining the spinal nerves and spinal cord. Alternatively, the antibody may be used to inhibit adhesions following abdominal surgery, or placed around the great vessels following an anterior approach to the spine or other regions. Importantly, the antibody may be used to inhibit adhesion formation adjacent to areas where growth factors are used to stimulate healing. The invention may further include the step of protecting the growth factors and/or the area of the body where stimulated healing is desired from the antibodies to the growth factors. As a further option, other medications or therapeutic substances may be added to the antibody(ies) to enhance healing or effectiveness.
<P>PROBLEM TO BE SOLVED: To provide a new pharmaceutical composition useful as an antibacterial agent for bacterial strains of the genus Propionibacterium.  <P>SOLUTION: The pharmaceutical composition comprises a new cyclic compound isolated from new Streptomyces sp. Q34752 strain and Q47152 strain as an active ingredient. The pharmaceutical composition has an excellent antibacterial activity against the bacterial strains of the genus Propionibacterium, especially Propionibacterium acnes, etc., and is useful as the antibacterial agent especially for treatment, etc., of acne vulgaris. The pharmaceutical composition has good anti-inflammatory activity and is useful for prophylaxis or therapy of various inflammatory diseases.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A water-soluble partial ester of (a) a water-soluble oxyalkylated sterol and (b) a copolymer of an a ,b -unsaturated carboxylic anhydride with an ethylenically unsaturated monomer, containing not more than 25% of the carboxyl groups present as ester groups of the sterol is claimed.  The copolymer may be derived from (i) an anhydride which is maleic, chloroitaconic, maleic, citraconic, methylene malonic, or benzyl maleic, and (ii) methyl ethyl or isobutyl vinyl ether, ethylene, styrene, vinyl acetate, chloride or stearate, methyl acrylate, acrylonitrile or N-vinyl pyrrolidone.  The sterol may be cholesterol, lanolin, cholestanol, stigmasterol, b -or g -sitosterol or lathosterol and is oxyalkylated by condensing with e.g. ethylene, propylene or butylene oxide.  The partial ester may be neutralized with sodium hydroxide or an amine.  Compositions may contain an aqueous solution of the partial ester and polyvinylpyrrolidone or mineral oil and sodium hydroxide. These compositions may be used as a hair pomade and hand lotion respectively.ALSO:A hair pomade in the form of a clear gel comprises an aqueous solution of (i) the partial ester of the condensation product of lanolin with ethylene oxide and a copolymer of vinyl methyl ether and maleic anhydride, (ii) and polyvinylpyrrolidone; the pH of the solution being adjusted to 5 with aqueous sodium hydroxide. A hand lotion comprises in the form of a creamy gel comprises a mixture of an aqueous solution of (i) above and mineral oil which has been neutralised to a pH of 6 with aqueous sodium hydroxide.
The invention provides an appendicitis treating drug, relates to applications of celery seed and the like in drugs or health, and belong to the field of natural drugs or health products, wherein the appendicitis treating drug is characterized by comprising 15-20 g of celery seed, 14-20 g of portulaca oleracea, 18-20 g of solanum septemlobum bunge, and 32-40 g of fallopia multiflora (thunb.) harald. According to the present invention, the preparation method comprises drying in the sun, grinding the dried celery seed into powder, grinding portulaca oleracea into powder, drying solanum septemlobum bunge in the sun, grinding the dried solanum septemlobum bunge into powder, drying fallopia multiflora (thunb.) harald in the sun, grinding the dried fallopia multiflora (thunb.) harald into powder, mixing the powders according to the ratio, and carrying out film pressing to obtain tablets, wherein about 24 g of the appendicitis treating drug is taken 3 times a day. The appendicitis treating drug of the present invention has high medical value.
Obesity is a focus of Japanese public health policy, due to Japanese individuals' high susceptibility to weight-related conditions. In contrast to global definitions, obesity is defined as a body-mass-index (BMI) of ≥25 kg/m2 in Japan. Despite public efforts, rates of obesity have not decreased over the past decade. To better understand its societal impact, we examined the economic, quality of life (QoL), and complications burden of obesity in Japan. Electronic databases were searched for English and Japanese-language publications from 2005 to December 2020 reporting on adults with obesity in Japan; other diseases were excluded, with no restriction on intervention. Outcomes of interest included costs or resource use, QoL, risk of complications, and other clinical outcomes. We identified 137 studies, including 19 reporting on economic evidence, eight reporting on QoL, and 115 reporting on the relationship between obesity and the risk of complications or mortality. The studies consistently showed that Japanese adults with obesity (BMI ≥25 kg/m2) are at increased risk of complications vs. normal weight adults. They also confirmed higher total and medical costs, resource use, and hospitalization costs among adults with obesity vs. normal weight adults. In addition, the studies confirmed a considerable impact of obesity on physical and mental aspects of QoL. Overall, this study found that obesity in Japan is associated with a substantial burden. Japanese people are at risk even with BMI ≥25-<30 kg/m2, which are generally considered as pre-obese in other countries.
OBJECTIVE: The current study aimed to investigate the baseline immune and inflammatory features and in-hospital outcomes of patients infected with the Omicron variant (PIWO) who presented with different disease severities during the first wave of mass Omicron infections in the Chinese population has occurred.
METHOD: A cross-sectional study was conducted on 140 hospitalized PIWO between December 11, 2022, and February 16, 2023. The clinical features, antibodies against SARS-CoV-2, immune cells, and inflammatory cytokines among mildly, severely, and critically ill PIWO at baseline and during follow-up period were compared.
RESULT: Patients with severe (n = 49) and critical (n = 35) disease were primarily male, needed invasive mechanical ventilation treatment, and exhibited higher mortality than those with mild disease (n = 56). During acute infection, SARS-CoV-2-specific antibody levels fluctuated with disease severity, serum antibodies increased and the incidence of severe cases decreased in critically ill PIWO over time. Antibody titers in severe or critical PIWO with no antibody responses at baseline did not increase significantly over time. Meanwhile, CD4+T cell, CD8+T cell, and natural killer cell counts were negatively correlated with disease severity, whereas interleukin (IL)-6 and IL-10 levels were positively correlated. In addition, combined diabetes, immunosuppressive therapy before infection, serum amyloid A, IL-10 and neutrophil counts were independently associated with severe and critical illness in PIWO. Among the 11 nonsurvivors, 8, 2, 1 died of respiratory failure, sudden cardiac death, and renal failure, respectively. Compared with survivors, nonsurvivors exhibited lower seropositivity of SARS-CoV-2-specific antibody, reduced CD3+T and CD4+T cell counts, and higher IL-2R, IL-6, IL-8, and IL-10 levels. Of note, lactate dehydrogenase was a significant risk factor of death in severe or critically ill PIWO.
CONCLUSION: This present study assessed the dynamic changes of SARS-CoV-2-specific antibodies, immune cells and inflammatory indexes between severely and critically ill PIWO. Critical and dead PIWO featured compromised humoral immune response and excessive inflammation, which broadened the understanding of the pathophysiology of Omicron infection and provides warning markers for severe disease and poor prognosis.
PURPOSE OF REVIEW: Climate change is predicted to increase the frequency and severity of exposure to hot environments. This can impair health, physical performance, and productivity for active individuals in occupational and athletic settings. This review summarizes current knowledge and recent advancements in nutritional strategies to minimize the impact of exertional-heat stress (EHS). RECENT FINDINGS: Hydration strategies limiting body mass loss to < 3% during EHS are performance-beneficial in weight-supported activities, although evidence regarding smaller fluid deficits (< 2% body mass loss) and weight-dependent activities is less clear due to a lack of well-designed studies with adequate blinding. Sodium replacement requirements during EHS depends on both sweat losses and the extent of fluid replacement, with quantified sodium replacement only necessary once fluid replacement > 60-80% of losses. Ice ingestion lowers core temperature and may improve thermal comfort and performance outcomes when consumed before, but less so during activity. Prevention and management of gastrointestinal disturbances during EHS should focus on high carbohydrate but low FODMAP availability before and during exercise, frequent provision of carbohydrate and/or protein during exercise, adequate hydration, and body temperature regulation. Evidence for these approaches is lacking in occupational settings. Acute kidney injury is a potential concern resulting from inadequate fluid replacement during and post-EHS, and emerging evidence suggests that repeated exposures may increase the risk of developing chronic kidney disease. Nutritional strategies can help regulate hydration, body temperature, and gastrointestinal status during EHS. Doing so minimizes the impact of EHS on health and safety and optimizes productivity and performance outcomes on a warming planet.
Ditropan® is indicated for the treatment of urge urinary incontinence, however patients tend to discontinue the medication or decrease the dose due to anticholinergic side effects. OROS® oxybutynin, a continuous release formulation, is expected to have fewer anticholinergic side effects than Ditropan® and may provide equal or better efficacy compared to Ditropan®. This is a randomized, multi-center, double-blind, parallel group, dose-escalation study comparing the efficacy and safety of OROS® oxybutynin to Ditropan® for the treatment of urge or mixed urinary incontinence at the minimum effective dose (MED), the maximum tolerated dose (MTD), or the maximum allowable dose (MAD) permitted under this protocol. Patients in both treatment groups begin study drug treatment at an oxybutynin dose of 5 mg per day. The dose is changed in 5 mg increments at 4- to 7-day intervals, depending on the safety and efficacy of the current dose. The maximum allowable dose for Ditropan® is 20 mg per day, which is the maximum daily adult dose specified in its labeling. Because controlled delivery of oxybutynin by an OROS® dosage form could potentially reduce side effects, it is believed that the drug could possibly be tolerated at doses higher than 20 mg per day. Consequently, the maximum allowable dose for OROS® oxybutynin is 30 mg per day, administered as a single daily dose. The primary measures of effectiveness include the change from baseline in the following assessments: the number of urge urinary incontinence episodes per week, the total number of urinary incontinence episodes, and total void frequency (normal and incontinent). Safety evaluations include the incidence of adverse events, physical examination and medical history, clinical laboratory tests, urinalysis, electrocardiograms (ECGs), vital signs, and the Anticholinergic Effects Assessment (ACEA) questionnaire.

OROS® (oxybutynin chloride) 5 mg tablets, one to six tablets per day (5 mg/day to 30 mg/day) as a single morning oral dose for 11 days up to 70 days, and Ditropan (oxybutynin chloride) 5 mg tablets, one to four tablets per day orally (5 mg per day to 5 mg four times per day) for 10 daysup to 61 days.
Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
PURPOSE: To evaluate the impact of the timing of MRI on the prediction of survival and morbidity in patients with CDH, and whether serial measurements have a beneficial value.
METHODS: This retrospective cohort study was conducted in two perinatal centers, in Germany and Italy. It included 354 patients with isolated CDH having at least one fetal MRI. The severity was assessed with the observed-to-expected total fetal lung volume (o/e TFLV) measured by two experienced double-blinded operators. The cohort was divided into three groups according to the gestational age (GA) at which the MRI was performed (< 27, 27-32, and  > 32 weeks' gestation [WG]). The accuracy for the prediction of survival at discharge and morbidity was analyzed with receiver operating characteristic (ROC) curves. Multiple logistic regression analyses and propensity score matching examined the population for balance. The effect of repeated MRI was evaluated in ninety-seven cases.
RESULTS: There were no significant differences in the prediction of survival when the o/e TFLV was measured before 27, between 27 and 32, and after 32 WG (area under the curve [AUC]: 0.77, 0.79, and 0.77, respectively). After adjustment for confounding factors, it was seen, that GA at MRI was not associated with survival at discharge, but the risk of mortality was higher with an intrathoracic liver position (adjusted odds ratio [aOR]: 0.30, 95% confidence interval [95%CI] 0.12-0.78), lower GA at birth (aOR 1.48, 95%CI 1.24-1.78) and lower o/e TFLV (aOR 1.13, 95%CI 1.06-1.20). ROC curves showed comparable prediction accuracy for the different timepoints in pregnancy for pulmonary hypertension, the need of extracorporeal membrane oxygenation, and feeding aids. Serial measurements revealed no difference in change rate of the o/e TFLV according to survival.
CONCLUSION: The timing of MRI does not affect the prediction of survival rate or morbidity as the o/e TFLV does not change during pregnancy. Clinicians could choose any gestational age starting mid second trimester for the assessment of severity and counseling.
The participants will be randomized into two groups, those who use the Buzzy system (experimental), and routine IV start (control). Prior to knowing their group, all patients will answer the "Before Intravenous Catheterization" portion of the form in order to eliminate bias. After this portion is complete, their group (experimental vs control) will be determined from opening a blinded envelope.

A tourniquet will be placed, followed by the Buzzy stimulation device (if in the experimental group). An alcohol swab will be used and then a 22 gauge IV catheter will be inserted, connected to fluids, and secured with tape. The antecubital fossa or the dorsal hand/wrist will be the only sites used in the study. All participants will fill out the post-insertion questions on the form and those patients that used the Buzzy system will then fill out the several specific questions related to the experimental group. This will conclude the patient's involvement in the study. The patient will then continue with treatment as planned. We will plan to exclude cases where the IV is not obtained on the first attempt, if a smaller or larger gauge IV catheter is required, or if an insertion site not listed above is required. The case will be excluded if adjunctive steps are taken to obtain IV access (i.e. Oral sedation, nitrous oxide, heat packs).
In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
The active ingredient in omeprazole delayed-release capsules, USP is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is:

Omeprazole Structural Formula

Omeprazole, USP is a white to off-white crystalline powder that melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions. 

Omeprazole is supplied as delayed-release capsules for oral administration. Each delayed-release capsule contains either 10 mg, 20 mg or 40 mg of omeprazole in the form of enteric-coated granules with the following inactive ingredients: cetyl alcohol, disodium phosphate, hydroxy propyl methylcellulose phthalate, lactose anhydrous, povidone, sodium lauryl sulfate, sucrose and talc. The capsule shells and imprinting inks have the following inactive ingredients: ammonium hydroxide, D&C Yellow # 10, FD&C Blue # 2 Aluminum Lake, FD&C Green # 3, gelatin, propylene glycol, shellac and titanium dioxide.
Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) two times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.